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STUDY PROTOCOL

Open Access

Progestogens to prevent preterm birth in twin
pregnancies: an individual participant data metaanalysis of randomized trials
Ewoud Schuit1*, Sarah Stock2, Rolf HH Groenwold1, Kimberly Maurel3, C Andrew Combs4, Thomas Garite5,
Cathy Y Spong6, Elizabeth A Thom7, Dwight J Rouse8, Steve N Caritis9, George R Saade10, Julia M Zachary7,
Jane E Norman2, Line Rode11, Katharina Klein12, Ann Tabor11, Elçin Çetingöz13, John C Morrison14,
Everett F Magann15, Christian M Briery16, Vicente Serra17, Alfredo Perales18, Juan Meseguer19, Anwar H Nassar20,
Arianne C Lim21, Karel GM Moons1, Anneke Kwee22 and Ben Willem J Mol21

Abstract
Background: Preterm birth is the principal factor contributing to adverse outcomes in multiple pregnancies.
Randomized controlled trials of progestogens to prevent preterm birth in twin pregnancies have shown no clear
benefits. However, individual studies have not had sufficient power to evaluate potential benefits in women at
particular high risk of early delivery (for example, women with a previous preterm birth or short cervix) or to
determine adverse effects for rare outcomes such as intrauterine death.
Methods/design: We propose an individual participant data meta-analysis of high quality randomized, doubleblind, placebo-controlled trials of progestogen treatment in women with a twin pregnancy. The primary outcome
will be adverse perinatal outcome (a composite measure of perinatal mortality and significant neonatal morbidity).
Missing data will be imputed within each original study, before data of the individual studies are pooled. The
effects of 17-hydroxyprogesterone caproate or vaginal progesterone treatment in women with twin pregnancies
will be estimated by means of a random effects log-binomial model. Analyses will be adjusted for variables used in
stratified randomization as appropriate. Pre-specified subgroup analysis will be performed to explore the effect of
progestogen treatment in high-risk groups.
Discussion: Combining individual patient data from different randomized trials has potential to provide valuable,
clinically useful information regarding the benefits and potential harms of progestogens in women with twin
pregnancy overall and in relevant subgroups.

Background
Preterm birth in twins

Preterm birth in multiple pregnancies is a major public
health concern. Stillbirths and neonatal deaths in twins
are 3 and 6 times higher than in singletons and a disproportionate amount of long-term morbidity is associated with multiple pregnancies [1]. Preterm birth is
the principal factor contributing to these adverse outcomes, with 50% of twin pregnancies delivering before
* Correspondence: e.schuit@umcutrecht.nl
1
Julius Centre for Health Sciences and Primary Care, University Medical
Centre Utrecht, Utrecht, the Netherlands
Full list of author information is available at the end of the article

37 weeks and 9% delivering before 32 weeks [2].
Improving outcomes in multiple pregnancies is a goal of
modern obstetrics, but as yet, few interventions have
been proven to be of benefit in this group. Thirty-three
to 56% of preterm births in twins are due to spontaneous preterm labor, making the prevention of preterm
labor an attractive strategy [2,3].
Progestogens to prevent preterm birth

Randomized trials in singleton pregnancies have suggested that antenatal progestogens (including vaginal
progesterone and synthetic progestogens such as 17hydroyprogesterone caproate [17-OHPC]) prevents
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preterm delivery in women who are at high risk of preterm delivery because of a previous preterm delivery
[4,5] or a short cervix [6]. These trials have led investigators to examine whether antenatal progestogens could
decrease preterm birth in multiple pregnancies.
Six randomized controlled trials of progestogens to
prevent preterm birth in twin pregnancies have now
been published, two large trials from the USA [7,8] and
one from the UK [9] and three smaller trials from Turkey [10], the UK [6] and the USA [11]. These studies
randomized women to either 17-OHPC/vaginal progesterone pessary, and placebo. One study, which included
67 women with twin pregnancies, 100 mg of vaginal
progesterone was found to reduce delivery before 37
weeks gestation (OR 3.48 [1.2-10.5]) [10]. In all other
studies [6,9,7], treatment with 17-OHPC or vaginal progesterone did not lead to any significant reduction in
preterm delivery or fetal loss. In the two largest trials,
however, a non-significant increase in intrauterine death
was seen in the treatment group [8,9]. Furthermore,
there was found a significant difference in median gestational age favoring placebo, in the other large trial [7].
We are aware of five other trials of progestogens in
multiple pregnancy that are nearing completion or publication [12-16]. In total these trials have included 3,522
women and more than 7,000 infants. Combining data
from these high-quality clinical trials has potential to
provide valuable information regarding the benefits and
potential harms of progestogens.
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bias that may arise through selective reporting [17]. Secondly, IPD allows for exploration of a differential treatment effect in relevant subgroups (i.e. treatment
covariate interactions), for example, women with a
monochorionic twin pregnancy and women with a short
cervix [18]. Since IPD meta-analyses include more
detailed data on a patient level than aggregated data
meta-analyses, statistical power to carry out informative
subgroup analyses is higher. Furthermore, flexibility of
subgroup analyses is enhanced, thus the estimated subgroup effects may be less influenced by misclassification
and bias. IPD meta-analysis therefore allows for a valid
assessment of differences in treatment effects across subgroups [19]. Thirdly, IPD allows time-to-event analysis.
Conventional meta-analysis only allows a pooled estimate
of treatment effect at specified cut-points, i.e. delivery
before 32, 34 or 37 weeks. The combined analysis of individual data however, can take account of the time
between the initiation of treatment and the outcome of
interest [20]. This allows time-to-delivery analysis with
the construction of Kaplan-Meier analysis and the performance of Cox regression. This means associations
between the timing and duration of progestogen treatment and preterm birth and intrauterine death can be
explored. This is important because most published trials
have reported a non-significant trend towards a shorter
duration of pregnancy after the use of progestogens in
women with a multiple pregnancy [8,9,21,22].

Methods/designs
Rationale for an IPD meta-analysis

Criteria for inclusion of studies in IPD

Aggregated data meta-analysis involves synthesis of estimates from clinical trials. This allows for a more robust
estimate of the overall treatment effect of progestogen
on multiple pregnancies as well as a more conclusive
evaluation of any harmful effects. This is particularly
important, as two published RCTs of progestogens in
twins have shown a non-significant trend for increased
intrauterine death with progestogen treatment [8,9]. A
potential problem in aggregated data meta-analyses is
that primary outcomes of clinical trials as well as subgroups defined in clinical trials can differ, which makes
it impossible to pool the results of different studies. An
Individual participant data (IPD) meta-analysis overcomes this problem as it involves synthesis of individual
level data from clinical trials. This allows for the same
robust estimate of the treatment effect and harmful
effects as in aggregated data meta-analysis, only now
more flexibility is possible regarding the choice of endpoints, subgroups and potential harms.
Performing an IPD meta-analysis as opposed to an
aggregated data meta-analysis has further advantages.
Firstly, IPD allows standardization of inclusion and exclusion criteria and analysis across studies, independent of

We propose an IPD meta-analysis of randomized controlled trials of 17- OHPC or vaginal progesterone versus placebo in women with twin pregnancies.
Participants

Inclusion criteria will be women with twin pregnancies,
with chorionicity and gestation confirmed by ultrasound,
who were included in a RCT comparing progestogens
with placebo for the prevention of preterm birth.
Women with congenital abnormalities, contraindications
to progestogen treatment and cervical cerclage will be
excluded.
Although studies have been performed in women with
triplet pregnancies [12,21,22] these will not be included in
the IPD meta-analysis. There appear to be differences in
the response to progestogens in women with singleton
and twin pregnancies, therefore further differences might
be anticipated between women with twins and those with
higher order multiples. As the number of trial participants
with triplet pregnancies is comparatively small compared
to the number with twin pregnancies, excluding these
women should not negatively affect the power of the
meta-analysis, whilst ensuring the group is as homogenous
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as possible. Exclusion of triplet pregnancies from the analyses will not compromise the validity of the study since
randomization was stratified for twin or higher order multiple in the studies that included both twin and triplet
pregnancies [7,8,12,21,22].
Intervention

The intervention will be either weekly intramuscular
injection of 17-hydroxyprogesterone caproate (17OHPC) or daily vaginal progesterone. As these treatments may act differently and have different distribution
profiles we will analyze the results of the two types of
treatment separately.
Outcome measures

The primary outcome will be adverse perinatal outcome,
a composite outcome of perinatal death, defined as
death before discharge from the hospital, and significant
neonatal morbidity at discharge, defined as one or more
of respiratory distress syndrome (RDS) requiring ventilation for ≥ 24 hr, bronchopulmonary dysplasia (BPD),
intraventricular hemorrhage (IVH) grade III or IV), periventricular leucomalacia (PVL), necrotizing enterocolitis
(NEC) grade II or more) culture proven sepsis, retinopathy of prematurity (ROP) requiring treatment.
Secondary outcomes will be intrauterine death < 32
weeks or preterm birth < 32 weeks; intrauterine death <
35 weeks or preterm birth < 35 weeks; intrauterine
death < 37 weeks or preterm birth < 37 weeks; intrauterine death; fetal loss < 28 weeks or early preterm birth
< 28 weeks gestation; time to delivery or death. If data
is detailed enough, preterm birth will be analyzed separately for spontaneous preterm birth and indicated preterm birth.
Subgroup analyses

Subgroup analyses will be performed for the primary
outcome only, in the following groups
- each of ultrasonographically diagnosed monochorionic and dichorionic twins
- women who completed ≥ 90% of treatment
- women with a cervical length < 25 mm on baseline
assessment (in studies where transvaginal cervical length
measurement was specified in protocol)
- women with a prior spontaneous preterm birth < 37
weeks
- ethnicity
- each dose of vaginal progesterone, e.g. ≤ 100 mg versus ≥ 200 mg.
Identification of studies

We will perform an electronic search of the Cochrane
Central Register of Controlled Trials (CENTRAL),
PubMed, MEDLINE and ClinicalTrials.gov for published
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or registered randomized controlled trials including
women with twin pregnancy that were randomly allocated to treatment with progestogens (including vaginal
progesterone and 17-hydroxyprogesterone caproate) or
placebo in the second or third trimester with the intention to prevent preterm birth. We will use the search
terms “preterm birth” AND ["progesterone” OR “17
hydroxyprogesterone caproate” OR “progestogen"] AND
["pregnancy multiple” OR “pregnancy twin"] AND “randomized controlled trial” AND “human”.
Two review authors (ES and SS) will independently
assess inclusion criteria and study quality and risk of
bias. A third author (BWJM) will review studies in
which there is any disagreement about study quality.
Risks of bias will be assessed in all of the identified studies based on [23]:
- sequence generation (i.e. computer generated random number, use of random number table or other
truly random process)
- allocation concealment (i.e. web-based or telephone
central randomization or consecutively numbered sealed
opaque envelopes)
- blinding for participants, study personnel and outcome assessors
- Incomplete outcome data
- Selective outcome reporting
- Other sources of bias
In cases where study quality is not clear from trial
protocols or publications, then the authors will be contacted for clarification.
The corresponding authors of eligible studies will be
approached to take part in the IPD meta-analysis. They
will be invited to take part if the study is complete and
data available by 1st July 2011.
Data quality will be independently assessed by two
review authors (ES and SS). A third author (BWJM) will
review data in which there is any disagreement about
quality. Only studies with adequate outcome data (<
10% participant attrition or exclusion, with full reporting
of reasons for withdrawals and protocol violations and
no imbalance in drop-outs across groups) and adequate
reporting (all of the study’s pre-specified outcomes and
all expected outcomes of interest made available) will be
included.
Analysis

Overall effects of each treatment (17-OHPC and vaginal
progesterone) in women with twin pregnancies will be
estimated in the pooled IPD. Descriptive comparisons
between studies will be conducted to assess betweenstudy differences. We assume the data to be missing at
random (MAR), therefore observed patient characteristics will be used to impute missing data, by means of
multiple imputation [24]. Missing data will be imputed
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within each original study, before data of the individual
studies are pooled. Treatment effects will be estimated
by means of a random effects log-binomial model and,
hence, the measure of association is the risk ratio. The
presence of heterogeneity of outcomes across trials will
be assessed using the I 2 measure [25]. Heterogeneity
across studies and dependency between data originating
from the same study will be taken into account by fitting a random intercept for each original study. If necessary, analyses will be adjusted for variables used in
stratified randomization. Furthermore, dependency
between children born from the same pregnancy will be
accounted for by means of generalized estimating equations (GEE) [26]. To investigate subgroup effects, the
treatment effects will also be estimated within strata
based on single subgrouping variables, as well as using
an interaction term in the regression model.
Time-to-delivery analysis will be performed with
Kaplan-Meier analysis and Cox proportional hazards
regression analysis. Again, dependency between data originating from the same study will be taken into account by
conducting a stratified analysis (stratified by study) [27].
We will perform subgroup analysis with pooled individual datasets of women stratified by the pre-specified criteria outlined above. Where available we will plot cervical
length against gestational age of cervical length measurement. When differences in gestational age explain differences in length, we will apply standardization for
gestational age. Differences in cervical length between
the studies will also be explored. We will assess the

absolute value of cervical length (corrected for gestational
age differences) as well as the percentiles of cervical
length (5th, 10th and 25th) in each dataset. We will
assess interaction between the treatment effect of progestogens and cervical length, using both time to delivery
and the primary and secondary endpoints. To ensure that
subgroup effects are not confounded by between-trial differences, dependency between data originating from the
same trial will be taken into account using a random
intercept for every study in the regression model [18].

Discussion
The proposed IPD meta-analysis is necessary to determine whether progestogen treatment in twin pregnancy
is beneficial or harmful. This is the first study that combines data on the effect of progestogens in twins and
the proposed IPD methodology will maximize the
impact of results.
The protocol for the individual participant data metaanalysis has been designed with input from the authors
of ten randomized controlled trials of progestogens in
women with twin pregnancies, many of which have
been published in high impact factor journals (Table 1).
All authors have committed to providing data if their
studies meet inclusion criteria. In total these trials have
included 3,498 women and almost 7,000 infants, allowing the meta-analysis to explore effects of progestogens
on rare outcomes and in high-risk subgroups. We
anticipate it will provide definitive data synthesis guiding
clinical practice and future research in this area.

Table 1 Overview of the studies published by authors consulted when planning the IPD meta-analysis
Study

Period

Briery[11]

06/04-06/10 30

N

250 mg 17-OPHC or placebo delivery before 35 completed weeks’ of gestation

Intervention

Primary outcome

Cetingoz[10]

12/04-02/07 67

100 mg vaginal
progesterone or placebo

Lim[12]

08/06-07/09 654 250 mg 17-OHPC in 1 mL
castor oil or placebo

Combs[7]

11/04-02/10 240 250 mg 17-OHPC or placebo composite outcome (RDS, Oxygen therapy at 28d, Neonatal sepsis, Pneumonia,
IVH grade III or worse, periventricular leukomalacia, NEC, retinopathy of
prematurity, asphyxia)

Nassar[13]

10/06-10/10 290 250 mg 17-OPHC or placebo frequency of delivery prior to completed 37 weeks of gestation (259 days)

Norman[9]

12/04-04/08 500 Vaginal progesterone gel 90
mg or placebo

delivery or intrauterine death before 34 weeks of gestation

Rode[14]

06/06-09/10 650 200 mg vaginal
progesterone of placebo

incidence of delivery < 34 weeks

Rouse[8]

04/04-02/06 661 250 mg 17-OHPC in 1 mL
castor oil or placebo

composite outcome (delivery or fetal death before 35 completed weeks of
gestation)

delivery before 37 weeks
composite outcome (Severe RDS, BPD, IVH grade III or worse, NEC, proven sepsis
or death before discharge)

Rozenberg[15] 06/06-06/10 160 500 mg 17-OPHC or no
treatment

Interval between inclusion and delivery

Serra[16]

Preterm birth rate (< 37 weeks)

01/06-05/08 246 200 mg or 400 mg vaginal
progesterone or placebo
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17-OHPC: 17-alphahydroxyprogesterone caproate; GEE: Generalized
estimating equations; IPD: Individual participant data; MAR: missing at
random; RCT: randomized controlled trial.
Acknowledgements
We would like to acknowledge all researchers and research nurses as well as
the staff of the labor wards of the participating centers in the studies
contributing to this individual patient data meta-analysis.
Author details
1
Julius Centre for Health Sciences and Primary Care, University Medical
Centre Utrecht, Utrecht, the Netherlands. 2MC Centre for Reproductive
Health, University of Edinburgh, Edinburgh, Scotland, USA. 3The Centre for
Research, Education & Quality (CREQ), Obstetrix Medical Group, Fountain
Valley, California, USA. 4Obstetrix Medical Group, San Jose, California, USA.
5
The Centre for Research, Education & Quality (CREQ), Obstetrix Medical
Group, Steamboat Springs, Colorado, USA. 6National Institute of Child Health
and Human Development, Bethesda, Maryland, USA. 7The Biostatistics
Centre, George Washington University, Rockville, MD, USA. 8Department of
Obstetrics and Gynecology, Brown University, Providence, Rhode Island and
Providence Plantations, USA. 9Department of Obstetrics and Gynecology,
Magee Womens Hospital, University of Pittsburgh, Pittsburgh, USA.
10
Department of Obstetrics and Gynecology, University of Texas Medical
Branch, Galveston, USA. 11Department of Fetal Medicine 4002, Copenhagen
University Hospital, Rigshospitalet, Copenhagen, Denmark. 12Department of
Obstetrics and Feto maternal Medicine, Medical University of Vienna, Vienna,
Austria. 13Department of Obstetrics and Gynecology, Zeynep Kamil Women
and Children Diseases Education and Research Hospital, Uskudar, Istanbul,
Turkey. 14Department of Obstetrics and Gynecology, University of Mississippi
Medical Centre, Jackson, USA. 15Department of Obstetrics and Gynecology,
University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
16
Department of Obstetrics and Gynecology, Willis Knighton Medical Centre,
Shreveport, Louisiana, USA. 17Maternal-Fetal Medicine Unit, Instituto
Valenciano de Infertilidad, University of Valencia, Valencia, Spain.
18
Department of Obstetrics and Gynecology, University Hospital La Fe,
Valencia, Spain. 19Departamento de Obstetricia y Ginecología, Hospital
Universitario Virgen de la Arrixaca, Murcia, Spain. 20Department of Obstetrics
and Gynecology, American University of Beirut, Beirut, Lebanon.
21
Department of Obstetrics and Gynecology, Academic Medical Centre,
Amsterdam, the Netherlands. 22Department of Obstetrics, and Gynecology,
University Medical Centre Utrecht, Utrecht, the Netherlands.

Page 5 of 6

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.
15.

16.
Authors’ contributions
ES, ACL and BWJM were involved in the concept and the design of the
study. ES and SS planned and wrote the initial protocol with significant
contributions by RHHG, AK, JEN, KGMM, DJR and BWJM. ES, SS, RHHG, KM,
CAC, TG, CYS, EAT, DJR, SNC, GRS, JMZ, JEN, LR, AT, JCM, EFM, VS, AP, JM,
ACL, KGMM, AK and BWJM participated in face-to-face meetings and/or
teleconferences to discuss the protocol, the design of the meta-analysis, the
choice of outcome measures and analysis strategies. KM, CAC, TG, CYS, EAT,
DJR, SNC, JEN, LR, KK, AT, EC, PR, JCM, EFM, CMB, VS, AP, JM, AHN, ACL,
BWJM were involved in the construction and design of one of the trials
included in the meta-analysis. All authors critically reviewed the subsequent
versions of the manuscript and approved the final manuscript.

17.
18.

19.

20.
21.

Competing interests
The authors declare that they have no competing interests.
22.
Received: 10 May 2011 Accepted: 15 March 2012
Published: 15 March 2012
References
1. Scottish Perinatal and Infant Mortality and Morbidity Report, 2007:
Edinburgh, Information Services Division, NHS Scotland; 2008, Ref Type:
Report.
2. Schaaf JM, Mol BW, bu-Hanna A, Ravelli AC: Trends in preterm birth:
singleton and multiple pregnancies in the Netherlands, 2000-2007. BJOG
2011, 118:1196-1204.

23.
24.

25.
26.

Chauhan SP, Scardo JA, Hayes E, Abuhamad AZ, Berghella V: Twins:
prevalence, problems, and preterm births. Am J Obstet Gynecol 2010,
203:305-315.
da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M: Prophylactic
administration of progesterone by vaginal suppository to reduce the
incidence of spontaneous preterm birth in women at increased risk: a
randomized placebo-controlled double-blind study. Am J Obstet Gynecol
2003, 188:419-424.
Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al:
Prevention of recurrent preterm delivery by 17 alphahydroxyprogesterone caproate. N Engl J Med 2003, 348:2379-2385.
Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH: Progesterone and the
risk of preterm birth among women with a short cervix. N Engl J Med
2007, 357:462-469.
Combs CA, Garite T, Maurel K, Das A, Porto M: 17-hydroxyprogesterone
caproate for twin pregnancy: a double-blind, randomized clinical trial.
Am J Obstet Gynecol 2011, 204:221-228.
Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al:
A trial of 17 alpha-hydroxyprogesterone caproate to prevent
prematurity in twins. N Engl J Med 2007, 357:454-461.
Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S, et al:
Progesterone for the prevention of preterm birth in twin pregnancy
(STOPPIT): a randomised, double-blind, placebo-controlled study and
meta-analysis. Lancet 2009, 373:2034-2040.
Cetingoz E, Cam C, Sakalli M, Karateke A, Celik C, Sancak A: Progesterone
effects on preterm birth in high-risk pregnancies: a randomized
placebo-controlled trial. Arch Gynecol Obstet 2011, 283:423-429.
Briery CM, Veillon EW, Klauser CK, Martin RW, Chauhan SP, Magann EF, et al:
Progesterone does not prevent preterm births in women with twins.
South Med J 2009, 102:900-904.
Lim AC, Schuit E, Bloemenkamp KW, Bernardus RE, Duvenkot JJ, Erwich JJ,
et al: 17-alpha hydroxyprogesterone caproate for the prevention of
adverse neonatal outcome in multiple pregnancies: a randomised
controlled trial. Obstet Gynecol 2011.
Nassar AH, Usta IM: Prevention of Preterm Delivery in Twin Pregnancies
by 17 Alpha-hydroxyprogesterone Caproate. ClinicalTrials gov Identifier:
NCT00141908 2006.
Rode L, Tabor A: Does Progesterone Prevent Very Preterm Delivery in
Twin Pregnancies? ClinicalTrials gov Identifier: NCT00329914 2010.
Rozenberg P: Efficacy of 17 Alpha-Hydroxyprogesterones Caproate for
the Prevention of Preterm Delivery. ClinicalTrials gov Identifier:NCT00331695
2006.
Serra VS: Natural progesterone and preterm birth in twins. ClinicalTrials
gov Identifier: NCT00480402 2007.
Riley RD, Lambert PC, bo-Zaid G: Meta-analysis of individual participant
data: rationale, conduct, and reporting. BMJ 2010, 340:c221.
Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG:
Meta-analysis of individual patient data from randomized trials: a review
of methods used in practice. Clin Trials 2005, 2:209-217.
Thompson SG, Higgins JP: Treating individuals 4: can meta-analysis help
target interventions at individuals most likely to benefit? Lancet 2005,
365:341-346.
Clarke MJ: Individual patient data meta-analyses. Best Pract Res Clin Obstet
Gynaecol 2005, 19:47-55.
Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY,
et al: Prevention of preterm birth in triplets using 17 alphahydroxyprogesterone caproate: a randomized controlled trial. Obstet
Gynecol 2009, 113:285-292.
Combs CA, Garite T, Maurel K, Das A, Porto M: Failure of 17hydroxyprogesterone to reduce neonatal morbidity or prolong triplet
pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol
2010, 203:248-249.
Higgins JP, Green S: Cochrane Handbook for Systematic Reviews of
Interventions The Cochrane Collaboration; 2011.
Donders AR, van der Heijden GJ, Stijnen T, Moons KG: Review: a gentle
introduction to imputation of missing values. J Clin Epidemiol 2006,
59:1087-1091.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency
in meta-analyses. BMJ 2003, 327:557-560.
Carlin JB, Gurrin LC, Sterne JA, Morley R, Dwyer T: Regression models for
twin studies: a critical review. Int J Epidemiol 2005, 34:1089-1099.

Schuit et al. BMC Pregnancy and Childbirth 2012, 12:13
http://www.biomedcentral.com/1471-2393/12/13

Page 6 of 6

27. Smith CT, Williamson PR, Marson AG: Investigating heterogeneity in an
individual patient data meta-analysis of time to event outcomes. Stat
Med 2005, 24:1307-1319.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2393/12/13/prepub
doi:10.1186/1471-2393-12-13
Cite this article as: Schuit et al.: Progestogens to prevent preterm birth
in twin pregnancies: an individual participant data meta-analysis of
randomized trials. BMC Pregnancy and Childbirth 2012 12:13.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

